Skip to main content
. 2021 Nov 24;13(621):eabi7826. doi: 10.1126/scitranslmed.abi7826

Fig. 6. humVHH_S56A/LALA-Fc/Gen2 neutralizes SARS-CoV-2 variants of concern.

Fig. 6.

(A) Surface view of SARS-CoV-2 RBD (gray) with VHH72 (green cartoon) and the N-terminal helixes of ACE2 (blue cartoon). The RBD-residues Lys417, Asn439, Leu452, Glu484, and Asn501 are indicated and marked in orange. (B) Binding of humVHH_S56A/LALA-Fc/Gen2, CB6, and palivizumab to SARS-CoV-1 spike was measured with the RBD replaced by WT, N439K, K417N, E484K, N501Y, or (K417N + E484K + N501Y) RBD of SARS-CoV-2 and expressed on the surface of 293 T cells. Data points represent the ratio of the MFI of transfected (GFP+) cells over the MFI of nontransfected (GFP−) cells, as determined by flow cytometry. (C) Neutralization of authentic SARS-CoV-2 virus determined by plaque reduction neutralization assay with threefold serial dilutions of the indicated VHH-Fc fusion constructs using BetaCov/Belgium/GHB-03021/2020, B1.1.7, or B.1.351 variant viruses.